Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.
A number of other research firms have also issued reports on TRIL. Zacks Investment Research lowered shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright set a $7.00 price target on shares of Trillium Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.33.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $11.05 on Friday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $13.30. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.01.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.